Literature DB >> 32035978

Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer.

Selena S Li1, Brooks V Udelsman1, Aparna Parikh2, Samuel J Klempner2, Jeffrey W Clark2, Eric J Roeland2, Jennifer Y Wo3, Theodore S Hong3, John T Mullen4.   

Abstract

BACKGROUND: Postoperative complication (POC) adversely impacts long-term survival in patients with gastric cancer, perhaps due in part to lower rates for receipt of multimodality therapy (MMT). We sought to determine the impact of POC on MMT completion rates and overall survival (OS) in patients with locally advanced gastric cancer. STUDY
DESIGN: We analyzed 206 patients with locally advanced gastric cancer undergoing curative-intent resection from 2001 to 2015. POCs were graded using Clavien-Dindo classification and survival outcomes were compared between groups.
RESULTS: One hundred and twenty patients underwent operation followed by chemoradiation therapy, 58 received perioperative chemotherapy, and 28 received total neoadjuvant therapy (TNT). Minor (Clavien-Dindo grade I to II) and major (Clavien-Dindo grade III to IV) POC occurred in 72 (35.0%) and 39 (18.9%) patients, respectively. At median follow-up of 37 months, the 3-year OS of patients experiencing a major, minor, or no POC were 33.3%, 56.9%, and 62.1% (p = 0.023), respectively. In contrast, there was no difference in 3-year OS rates in patients experiencing POC if they completed all intended MMT. Non-TNT patients who experienced a major POC were less likely to complete MMT (hazard ratio 0.36, p = 0.017), and a major POC in these patients had a significant impact on OS (hazard ratio 2.76, p = 0.011), and it did not in patients who completed MMT (hazard ratio 1.58, p = 0.336).
CONCLUSIONS: Major POC adversely affects long-term survival after gastrectomy for gastric cancer, at least in part via lower completion rates of MMT. Treatment strategy designed to ensure the completion of MMT, such as TNT, might be preferable, particularly for patients at high risk for POCs.
Copyright © 2020 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32035978     DOI: 10.1016/j.jamcollsurg.2019.12.038

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  12 in total

1.  Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor.

Authors:  Wei Peng; Jing Dai; Chao-Chan Liu; Dian Liu; Hua Xiao
Journal:  Front Oncol       Date:  2022-06-13       Impact factor: 5.738

2.  Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.

Authors:  Tian Yun; Sunan Wang; Bo Jiang; Changsong Wang; Nianlong Meng; Xutao Yuan; Yangkun Wang
Journal:  J Oncol       Date:  2020-10-13       Impact factor: 4.375

3.  The Influence of Heavy Metals on Gastric Tumorigenesis.

Authors:  Liang Wang; Congxiu Miao; Yuan He; Hanglong Li; Shasha Zhang; Keyan Li; Huimin Liu; Wushuang Li; Jiangman Zhao; Yue Xu; Hui Tang; Qiang Zhao
Journal:  J Oncol       Date:  2022-05-28       Impact factor: 4.501

4.  Adverse Prognostic Impact of Postoperative Complications After Gastrectomy for Patients With Stage II/III Gastric Cancer: Analysis of Prospectively Collected Real-World Data.

Authors:  Jeong Ho Song; Sejin Lee; Seohee Choi; Minah Cho; In Gyu Kwon; Yoo Min Kim; Taeil Son; Hyoung-Il Kim; Minkyu Jung; Woo Jin Hyung
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

5.  The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric Cancer.

Authors:  Toru Aoyama; Masato Nakazono; Kenki Segami; Shinsuke Nagasawa; Kazuki Kano; Takanobu Yamada; Yukio Maezawa; Kentaro Hara; Itaru Hashimoto; Hideaki Suematsu; Hayato Watanabe; Kosuke Takahashi; Masakatsu Numata; Hiroshi Tamagawa; Norio Yukawa; Yasushi Rino; Takashi Ogata; Takashi Oshima
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

6.  Impact of Preoperative Type 2 Diabetes Mellitus on the Outcomes of Gastric Cancer Patients Following Gastrectomy: A Propensity Score Matching Analysis.

Authors:  Yu-Xi Cheng; Wei Tao; Bing Kang; Xiao-Yu Liu; Chao Yuan; Bin Zhang; Dong Peng
Journal:  Front Surg       Date:  2022-03-08

7.  Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy.

Authors:  Hong Yu; Li Xu; Songcheng Yin; Jianlong Jiang; Chunhong Hong; Yulong He; Changhua Zhang
Journal:  Curr Oncol       Date:  2022-09-10       Impact factor: 3.109

8.  Sarcopenia in Patients With Normal Body Mass Index Is an Independent Predictor for Postoperative Complication and Long-Term Survival in Gastric Cancer.

Authors:  Xiangwei Sun; Jianfeng Xu; Xiaodong Chen; Weiteng Zhang; Wenjing Chen; Ce Zhu; Jing Sun; Xinxin Yang; Xiang Wang; Yingying Hu; Yiqi Cai; Xian Shen
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

9.  Association Among Blood Transfusion, Postoperative Infectious Complications, and Cancer-Specific Survival in Patients with Stage II/III Gastric Cancer After Radical Gastrectomy: Emphasizing Benefit from Adjuvant Chemotherapy.

Authors:  Hua Xiao; Yanping Xiao; Pan Chen; Hu Quan; Jia Luo; Gang Huang
Journal:  Ann Surg Oncol       Date:  2020-09-14       Impact factor: 5.344

10.  Effectiveness and safety of focused ultrasound ablation surgery compared with radiofrequency ablation in primary hepatocellular carcinoma treatment: a meta-analysis.

Authors:  Jian-Ying Zhang; Long Chen; Rong Ma; Chun-Mu Miao; Yun-Bing Wang
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.